This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, Q. N.
Right arrow Articles by Graybill, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, Q. N.
Right arrow Articles by Graybill, J. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2002, p. 1581-1582, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1581-1582.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of Zygomycetes

Qiu N. Sun,1,2 Annette W. Fothergill,3* Dora I. McCarthy,3 Michael G. Rinaldi,3,4 and John R. Graybill1,4

Division of Infectious Diseases (7811), Department of Medicine,1 The Fungus Testing Laboratory, Department of Pathology, The University of Texas Health Science Center at San Antonio,3 Audie L. Murphy Division, South Texas Veterans Health Care System, San Antonio, Texas 78229,4 Department of Dermatology, Beijing Union Medical University Hospital, Beijing, 100730, People's Republic of China2

Received 28 February 2001/ Returned for modification 24 August 2001/ Accepted 2 February 2002

In vitro antifungal susceptibility testing results of a new antifungal triazole, posaconazole (POS), were compared to results with amphotericin B (AMB), itraconazole (ITC), voriconazole (VRC), and fluconazole (FLC) against clinical agents of zygomycosis. The MICs of POS at which 50% and 90% of the isolates were inhibited were 0.25 and 4 µg/ml, respectively. POS was significantly more active than VRC and FLC and slightly more active than ITC. The results suggest that POS has significant potential for clinical development against the zygomycetes.

* Corresponding author. Mailing address: The Fungus Testing Laboratory, Department of Pathology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900. Phone: (210) 567-4131. Fax: (210) 567-4076. E-mail: fothergill{at}uthscsa.edu.

Antimicrobial Agents and Chemotherapy, May 2002, p. 1581-1582, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1581-1582.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • CHUA, A.-P., BILLINGS, S. D., BUDEV, M. M., MEHTA, A. C. (2009). Ulcerative leg nodules in a transplant recipient. Cleveland Clinic Journal of Medicine 76: 575-576 [Full Text]  
  • Khan, Z. U., Ahmad, S., Brazda, A., Chandy, R. (2009). Mucor circinelloides as a Cause of Invasive Maxillofacial Zygomycosis: an Emerging Dimorphic Pathogen with Reduced Susceptibility to Posaconazole. J. Clin. Microbiol. 47: 1244-1248 [Abstract] [Full Text]  
  • Morris, M. I. (2009). Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 66: 225-236 [Abstract] [Full Text]  
  • Rodriguez, M. M., Serena, C., Marine, M., Pastor, F. J., Guarro, J. (2008). Posaconazole Combined with Amphotericin B, an Effective Therapy for a Murine Disseminated Infection Caused by Rhizopus oryzae. Antimicrob. Agents Chemother. 52: 3786-3788 [Abstract] [Full Text]  
  • Espinel-Ingroff, A., Canton, E. (2008). Comparison of Neo-Sensitabs Tablet Diffusion Assay with CLSI Broth Microdilution M38-A and Disk Diffusion Methods for Testing Susceptibility of Filamentous Fungi with Amphotericin B, Caspofungin, Itraconazole, Posaconazole, and Voriconazole. J. Clin. Microbiol. 46: 1793-1803 [Abstract] [Full Text]  
  • Espinel-Ingroff, A., Johnson, E., Hockey, H., Troke, P. (2008). Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother 61: 616-620 [Abstract] [Full Text]  
  • Mikesch, J.-H., Rudat, A., Zuhlsdorf, M., Berdel, W. E., Mesters, R., Conrad, B., Becker, K., Fegeler, W., Anthoni, C. (2007). Subcutaneous Zygomycosis in Neutropenia. JCO 25: 4844-4845 [Full Text]  
  • Almyroudis, N. G., Sutton, D. A., Fothergill, A. W., Rinaldi, M. G., Kusne, S. (2007). In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents. Antimicrob. Agents Chemother. 51: 2587-2590 [Abstract] [Full Text]  
  • Schwarz, P., Lortholary, O., Dromer, F., Dannaoui, E. (2007). Carbon Assimilation Profiles as a Tool for Identification of Zygomycetes. J. Clin. Microbiol. 45: 1433-1439 [Abstract] [Full Text]  
  • Krishna, G., Sansone-Parsons, A., Martinho, M., Kantesaria, B., Pedicone, L. (2007). Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal Infection. Antimicrob. Agents Chemother. 51: 812-818 [Abstract] [Full Text]  
  • Torres-Narbona, M., Guinea, J., Martinez-Alarcon, J., Pelaez, T., Bouza, E. (2007). In Vitro Activities of Amphotericin B, Caspofungin, Itraconazole, Posaconazole, and Voriconazole against 45 Clinical Isolates of Zygomycetes: Comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob. Agents Chemother. 51: 1126-1129 [Abstract] [Full Text]  
  • Iwen, P. C., Sigler, L., Noel, R. K., Freifeld, A. G. (2007). Mucor circinelloides Was Identified by Molecular Methods as a Cause of Primary Cutaneous Zygomycosis. J. Clin. Microbiol. 45: 636-640 [Abstract] [Full Text]  
  • Espinel-Ingroff, A. (2006). Comparison of Three Commercial Assays and a Modified Disk Diffusion Assay with Two Broth Microdilution Reference Assays for Testing Zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with Posaconazole and Amphotericin B. J. Clin. Microbiol. 44: 3616-3622 [Abstract] [Full Text]  
  • Enoch, D. A., Ludlam, H. A., Brown, N. M. (2006). Invasive fungal infections: a review of epidemiology and management options.. J Med Microbiol 55: 809-818 [Abstract] [Full Text]  
  • Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., McNicholas, P. M. (2006). In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts.. Antimicrob. Agents Chemother. 50: 2009-2015 [Abstract] [Full Text]  
  • Sansone-Parsons, A., Krishna, G., Calzetta, A., Wexler, D., Kantesaria, B., Rosenberg, M. A., Saltzman, M. A. (2006). Effect of a Nutritional Supplement on Posaconazole Pharmacokinetics following Oral Administration to Healthy Volunteers.. Antimicrob. Agents Chemother. 50: 1881-1883 [Abstract] [Full Text]  
  • Schwarz, P., Bretagne, S., Gantier, J.-C., Garcia-Hermoso, D., Lortholary, O., Dromer, F., Dannaoui, E. (2006). Molecular Identification of Zygomycetes from Culture and Experimentally Infected Tissues. J. Clin. Microbiol. 44: 340-349 [Abstract] [Full Text]  
  • Antachopoulos, C., Meletiadis, J., Roilides, E., Sein, T., Walsh, T. J. (2006). Rapid Susceptibility Testing of Medically Important Zygomycetes by XTT Assay. J. Clin. Microbiol. 44: 553-560 [Abstract] [Full Text]  
  • Chamilos, G., Lewis, R. E., Kontoyiannis, D. P. (2006). Lovastatin Has Significant Activity against Zygomycetes and Interacts Synergistically with Voriconazole. Antimicrob. Agents Chemother. 50: 96-103 [Abstract] [Full Text]  
  • Greenberg, R. N., Mullane, K., van Burik, J.-A. H., Raad, I., Abzug, M. J., Anstead, G., Herbrecht, R., Langston, A., Marr, K. A., Schiller, G., Schuster, M., Wingard, J. R., Gonzalez, C. E., Revankar, S. G., Corcoran, G., Kryscio, R. J., Hare, R. (2006). Posaconazole as Salvage Therapy for Zygomycosis. Antimicrob. Agents Chemother. 50: 126-133 [Abstract] [Full Text]  
  • Pimentel, J. D., Dreyer, G., Lum, G. D. (2006). Peritonitis due to Cunninghamella bertholletiae in a patient undergoing continuous ambulatory peritoneal dialysis. J Med Microbiol 55: 115-118 [Abstract] [Full Text]  
  • Brown, J. (2005). Zygomycosis: An emerging fungal infection. Am J Health Syst Pharm 62: 2593-2596 [Abstract] [Full Text]  
  • Bialek, R, Konrad, F, Kern, J, Aepinus, C, Cecenas, L, Gonzalez, G M, Just-Nubling, G, Willinger, B, Presterl, E, Lass-Florl, C, Rickerts, V (2005). PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J. Clin. Pathol. 58: 1180-1184 [Abstract] [Full Text]  
  • Karanth, M, Taniere, P, Barraclough, J, Murray, J A (2005). A rare presentation of zygomycosis (mucormycosis) and review of the literature. J. Clin. Pathol. 58: 879-881 [Abstract] [Full Text]  
  • Spellberg, B., Edwards, J. Jr., Ibrahim, A. (2005). Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management. Clin. Microbiol. Rev. 18: 556-569 [Abstract] [Full Text]  
  • Gil-Lamaignere, C., Hess, R., Salvenmoser, S., Heyn, K., Kappe, R., Muller, F.-M. C. (2005). Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes. J Antimicrob Chemother 55: 1016-1019 [Abstract] [Full Text]  
  • Barron, M. A., Lay, M., Madinger, N. E. (2005). Surgery and Treatment with High-Dose Liposomal Amphotericin B for Eradication of Craniofacial Zygomycosis in a Patient with Hodgkin's Disease Who Had Undergone Allogeneic Hematopoietic Stem Cell Transplantation. J. Clin. Microbiol. 43: 2012-2014 [Abstract] [Full Text]  
  • Courtney, R., Sansone, A., Smith, W., Marbury, T., Statkevich, P., Martinho, M., Laughlin, M., Swan, S. (2005). Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease. J Clin Pharmacol 45: 185-192 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J. (2004). Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 42: 4419-4431 [Full Text]  
  • Courtney, R., Radwanski, E., Lim, J., Laughlin, M. (2004). Pharmacokinetics of Posaconazole Coadministered with Antacid in Fasting or Nonfasting Healthy Men. Antimicrob. Agents Chemother. 48: 804-808 [Abstract] [Full Text]  
  • Marty, F. M., Cosimi, L. A., Baden, L. R. (2004). Breakthrough Zygomycosis after Voriconazole Treatment in Recipients of Hematopoietic Stem-Cell Transplants. NEJM 350: 950-952 [Full Text]  
  • Dannaoui, E., Meis, J. F. G. M., Loebenberg, D., Verweij, P. E. (2003). Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis. Antimicrob. Agents Chemother. 47: 3647-3650 [Abstract] [Full Text]  
  • Courtney, R., Pai, S., Laughlin, M., Lim, J., Batra, V. (2003). Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults. Antimicrob. Agents Chemother. 47: 2788-2795 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»